Search Results - "Banki, E."

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin by Banki, E., Hajna, Zs, Kemeny, A., Botz, B., Nagy, P., Bolcskei, K., Toth, G., Reglodi, D., Helyes, Zs

    Published in Neuropharmacology (01-10-2014)
    “…We have earlier shown that PACAP-38 decreases neurogenic inflammation. However, there were no data on its receptorial mechanism and the involvement of its PAC1…”
    Get full text
    Journal Article
  2. 2

    Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy by Banki, E., Degrell, P., Kiss, P., Kovacs, K., Kemeny, A., Csanaky, K., Duh, A., Nagy, D., Toth, G., Tamas, A., Reglodi, D.

    Published in Peptides (New York, N.Y. : 1980) (01-04-2013)
    “…► PACAP has protective effects in diabetic nephropathy in rats. ► PACAP attenuates the morphological alterations in the diabetic kidney. ► PACAP conteracts…”
    Get full text
    Journal Article
  3. 3

    PACAP Immunoreactivity in Human Malignant Tumor Samples and Cardiac Diseases by Szanto, Z., Sarszegi, Zs, Reglodi, D., Nemeth, J., Szabadfi, K., Kiss, P., Varga, A., Banki, E., Csanaky, K., Gaszner, B., Pinter, O., Szalai, Zs, Tamas, A.

    Published in Journal of molecular neuroscience (01-11-2012)
    “…Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional neuropeptide having important roles in various physiological…”
    Get full text
    Journal Article
  4. 4

    Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons by Sághy, É, Payrits, M, Helyes, Zs, Reglődi, D, Bánki, E, Tóth, G, Couvineau, A, Szőke, É

    Published in Neuroscience (12-11-2015)
    “…Highlights • We provided the first evidence that maxadilan and BAY 55-9837 cause Ca2+ -influx in TRG neurons. • The TRG culture is an appropriate model to…”
    Get full text
    Journal Article
  5. 5

    Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth by Reglodi, D., Gyarmati, J., Ertl, T., Borzsei, R., Bodis, J., Tamas, A., Kiss, P., Csanaky, K., Banki, E., Bay, C., Nemeth, J., Helyes, Z.

    Published in Journal of endocrinological investigation (01-07-2010)
    “…Background : Since its discovery, several distinct effects of pituitary adenylate cyclase activating polypeptide (PACAP) have been established — predominantly…”
    Get full text
    Journal Article
  6. 6

    Examination of PACAP38-like immunoreactivity in different milk and infant formula samples by Csanaky, K, Reglődi, D, Bánki, E, Tarcai, I, Márk, L, Helyes, Zs, Ertl, T, Gyarmati, J, Horváth, K, Sántik, L, Tamás, Andrea

    Published in Acta physiologica Hungarica (01-03-2013)
    “…Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with special importance in reproductive and developmental processes. PACAP is…”
    Get more information
    Journal Article
  7. 7